

SAHA Patient: IV vs ORAL (200 mg/dose)




FIG. 1

Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS
Cohort I (200 mg/dose)




FIG. 2

SAHA Patients: ORAL / Cohort I (200 mg/dose)




FIG. 3

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS

Cohort I (200 mg/dose)






FIG. 4

Protocol 01-021 (ORAL SAHA)
 ARM A: SOLID TUMOR PATIENTS
 Cohort IIa (400 mg/dose)



12/19/01



12/27/01

FIG. 5

SAHA Patients: ORAL/Cohort II (400 mg/dose)

9-OS-400 10-OS-400

9-OS-400		10-OS-400	
IV	ORAL	IV	ORAL
Pre	Pre	Pre	Pre
2 hrs	2 hrs	2 hrs	2 hrs
6 hrs			
8 hrs			

Markers

+

-




FIG. 6

Protocol 01-021 (ORAL SAHA)
 ARM A: SOLID TUMOR PATIENTS
 Cohort IIa (400 mg/dose)




FIG. 7

SAHA Patients: ORAL/Cohort II (400 mg/dose)





FIG. 8

Oral 200 mg vs. 400 mg (Fasting)




Fig. 9A

Oral 200 mg vs. 400 mg (no-fasting)




Fig. 9B

IV 200 mg vs. 400 mg





Fig. 9C


Apparent Half-life of the Oral Dose



Blue=200 mg group (n=3-5); yellow=400 mg group (n=5-10)

Fig. 10

AUC of the Oral Dose



Blue=200 mg group (n=3-5); yellow=400 mg group (n=5-10)

Fig. 11

Bioavailability




Fig. 12




FIG. 13A





FIG. 13B






FIG. 13D




FIG. 13E

FIG. 14A





FIG. 14B






FIG. 14C




FIG. 14D




FIG. 14E





FIG. 15